Insulet (PODD) Stock Forecast & Price Target

Insulet is well positioned because its Omnipod platform addresses a large, underpenetrated diabetes market with a differentiated tubeless, pharmacy-channel model that is difficult for rivals to replicate, and its global base has already surpassed 600,000 insulin-dependent patients. The latest quarter showed the model’s operating leverage, with revenue of $842M up 19.6% cc, adjusted gross margin of 74.2%, adjusted operating margin of 22.0%, and adjusted EPS of $1.99, while U.S. growth was supported by a high-teens customer base and improving Type 2 retention. Management also raised full-year 2026 constant-currency growth guidance to 21-22%, lifted OUS growth to 32-33%, and approved an additional $1B share repurchase authorization, reinforcing confidence in durable demand, margin expansion, and shareholder returns.

Insulet is facing a fundamental slowdown in its U.S. growth trajectory as management guided 2027 toward the low end of the prior 9-14% range and total company growth to modestly below the mid-teens framework, citing new competition, stable retention and pricing, and tougher international comparisons. The bearish view is reinforced by emerging Type 2 churn and retention issues, stable utilization with limited benefit from 2026 initiatives, and the expectation that intensifying tubeless competition and trialing will pressure the multiple for an extended period. Although Omnipod remains the category leader with more than 600,000 users worldwide and a pipeline that includes Omnipod 6, iOS Libre 3+ LMR, and EVOLVE, the company appears to face a tougher path to sustain margins, growth, and credibility.